Clinical Trial Results:
A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody), ACZ885 (canakinumab, anti-IL1b antibody), or corticosteroids in patients with polymyalgia rheumatica, followed by an open label phase to assess safety and long term efficacy
Summary
|
|
EudraCT number |
2010-019395-73 |
Trial protocol |
GB DE IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v3(current) |
This version publication date |
02 Sep 2021
|
First version publication date |
15 Apr 2016
|
Other versions |
v1 , v2 |
Version creation reason |
|
Summary report(s) |
CPJMR001-2201 Results Registration Form as updated on clinicaltrials.gov printed on 17 Aug 2021 RRF |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.